<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01854814</url>
  </required_header>
  <id_info>
    <org_study_id>MAIN</org_study_id>
    <nct_id>NCT01854814</nct_id>
  </id_info>
  <brief_title>The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy Patients</brief_title>
  <acronym>MAIN</acronym>
  <official_title>The Effects of Mycophenolate Mofetil on Renal Outcomes in Patients With Advanced IgA Nephropathy: a Randomized Open-label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fan Fan Hou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <brief_summary>
    <textblock>
      The study is to evaluate the effect of Mycophenolate Mofetil compared with losartan alone on
      time to doubling of serum creatinine or the onset of end stage renal disease in patients with
      advanced IgA nephropathy who are treated with the maximal tolerated daily dose of
      losartan.The study will also assess the effects of MMF compared with losartan alone on the
      changes of urine albumin excretion and the changes in estimated glomerular filtration rate.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effects of mycophenolate mofetil on a composite renal outcomes in subjects with advanced IgA nephropathy</measure>
    <time_frame>3 years</time_frame>
    <description>Time to the first occurrence of a component of the composite renal endpoint:
Doubling of serum creatinine or the onset of end stage renal disease (ESRD) [needing chronic dialysis or renal transplantation or renal death]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the effects of mycophenolate mofetil on progression of CKD in subjects with advanced IgA nephropathy</measure>
    <time_frame>3 years</time_frame>
    <description>A decrease in eGFR of 30% or more and to a level of less than 60 ml/min at the exit visit if the baseline eGFR was 60 ml/min or more.
Or a decrease in eGFR of 50% or more at the exit visit if the baseline eGFR was less than 60 ml/min.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects of mycophenolate mofetil on the changes of proteinuria in subjects with advanced IgA nephropathy</measure>
    <time_frame>3 years</time_frame>
    <description>Changes of urinary protein excretion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects of mycophenolate mofetil rapid progression of CKD in subjects with advanced IgA nephropathy</measure>
    <time_frame>3 years</time_frame>
    <description>Time to 30% reduction in estimated glomerular filtration rate (eGFR); eGFR reduction greater than 5 ml/min/1.73m^2/year</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">232</enrollment>
  <condition>IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>mycophenolate mofetil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mycophenolate mofetil 1.5g/day and maximum tolerated labeled dose of losartan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>losartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>maximus tolerated labeled dose of losartan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Mycophenolate mofetil 1.5g/day plus maximum tolerated labeled dose losartan</description>
    <arm_group_label>mycophenolate mofetil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Maximum tolerated labeled dose of Losartan</description>
    <arm_group_label>losartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy-proven primary IgA nephropathy with urinary proteinuria excretion over 1g/24
             hour,subjects must meet 2 of the following criteria:

               1. global glomerular sclerosis plus focal segmental glomerular sclerosis ratio â‰¥50%

               2. eGFR 30 to 60 ml/min

               3. Hypertension (blood pressure over 140/90 mmHg or taking antihypertensive drugs)

        Exclusion Criteria:

          1. Secondary IgA nephropathy

          2. Familial IgA nephropathy

          3. Concomitant disease: cancer, infection, diabetes mellitus, connective tissue disease,
             abnormal liver function

          4. Pregnancy or breasting

          5. Inability to comply with study and follow-up procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fan Fan Hou, M.D., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of nephrology, Nanfang Hospital Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fan Fan Hou, M.D.,PhD</last_name>
    <phone>0086-20-61641591</phone>
    <email>ffhouguangzhou@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nanfang Hospital Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Wang, doctor</last_name>
      <phone>0086-020-61641591</phone>
      <email>wangjun1975@smu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Min Liang, doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun Wang, doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xun Zhang, doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun Ai, doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fourth People's Hospital Shenzhen</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiecheng Yang, MD</last_name>
      <phone>008613823123966</phone>
      <email>Yangtcpro@163.com</email>
    </contact>
    <investigator>
      <last_name>Tiecheng Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Institute of Nephrology, Guangdong Medical College</name>
      <address>
        <city>Zhanjiang</city>
        <state>Guangdong</state>
        <zip>524001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hua-feng Liu, PhD, MD</last_name>
      <phone>0759-2387583</phone>
      <email>hf-liu@263.net</email>
    </contact>
    <investigator>
      <last_name>Hua-feng Liu, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Tang SC, Tang AW, Wong SS, Leung JC, Ho YW, Lai KN. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int. 2010 Mar;77(6):543-9. doi: 10.1038/ki.2009.499. Epub 2009 Dec 23.</citation>
    <PMID>20032964</PMID>
  </reference>
  <reference>
    <citation>Frisch G, Lin J, Rosenstock J, Markowitz G, D'Agati V, Radhakrishnan J, Preddie D, Crew J, Valeri A, Appel G. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant. 2005 Oct;20(10):2139-45. Epub 2005 Jul 19.</citation>
    <PMID>16030050</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2013</study_first_submitted>
  <study_first_submitted_qc>May 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2013</study_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Fan Fan Hou</investigator_full_name>
    <investigator_title>Chief of Division of Nephrology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

